NR 565 Final Exam Prep Document | 2026/2027 Edition | 200
Verified Questions - 139 Questions with Answers
NR 565 Advanced Pharmacology Fundamentals Final Exam 2026-139 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for nursing students enrolled
in NR 565 Advanced Pharmacology Fundamentals at Chamberlain University. It features 200 verified
questions and answers that reflect the actual content and format of the 2026/2027 final exam. Each
question is accompanied by a detailed rationale to reinforce understanding of pharmacological
principles. This resource is designed to ensure a 100% guarantee of passing by providing the most
current and accurate study material available.
Key Features:
Pharmacokinetics and pharmacodynamics
Autonomic nervous system drugs
Cardiovascular pharmacology
Endocrine and metabolic disorders
Antimicrobial therapy
Special populations and safety
Updates for 2026:
- Updated to align with 2026/2027 Chamberlain curriculum changes
- Revised to include latest FDA drug approvals and safety alerts
- Enhanced rationales with evidence-based practice guidelines
- Added new questions on emerging pharmacogenomics and personalized medicine
- Reorganized content to mirror the exam blueprint weighting
Abstract:
This exam preparation document for NR 565 Advanced Pharmacology Fundamentals is a definitive resource for
nursing students seeking to excel in their final examination. Compiled from actual 2026/2027 exam questions, it
offers a comprehensive review of pharmacological principles essential for advanced nursing practice. The content
is systematically organized to cover major drug classes, mechanisms of action, therapeutic uses, adverse effects,
and nursing considerations. Each of the 200 questions is paired with a correct answer and a thorough rationale,
facilitating active learning and retention. The document also emphasizes clinical application, critical thinking, and
safe prescribing practices, aligning with the competencies expected of advanced practice nurses. By utilizing this
resource, students can confidently prepare for the exam and achieve a passing score with a 100% guarantee.
Keywords:
NR 565, Advanced Pharmacology, Final Exam, Chamberlain University, Verified Questions, Pharmacology
Fundamentals, 2026/2027, Nursing Exam Prep
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale
explaining why it is correct and why the other options are incorrect. This format enhances understanding of
pharmacological concepts and supports critical thinking.
Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Reflects the latest 2026/2027 exam blueprint and guidelines
Includes evidence-based rationales for each answer
Page 1
, Covers all major content areas as per the course syllabus
Verified for accuracy by pharmacology experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 ADME, receptor interactions, dose-response, 15%
Pharmacodynamics drug metabolism
Autonomic Nervous System 31-60 cholinergic, anticholinergic, adrenergic, 15%
Drugs antiadrenergic
Cardiovascular Pharmacology 61-90 antihypertensives, antiarrhythmics, 15%
anticoagulants, lipid-lowering agents
Endocrine and Metabolic 91-120 insulin, oral hypoglycemics, thyroid 15%
Disorders hormones, corticosteroids
Antimicrobial Therapy 121-150 antibiotics, antivirals, antifungals, resistance 15%
mechanisms
Special Populations and Safety 151-200 pregnancy, pediatrics, geriatrics, drug 25%
interactions, adverse effects
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min/1.73
m²) is currently on metformin and insulin glargine. The provider considers adding
dapagliflozin. Which of the following best describes the pharmacological rationale
and safety consideration?
A. Dapagliflozin is contraindicated at this eGFR, and its glycemic efficacy is
diminished, so an alternative agent should be considered.
B. Dapagliflozin is safe and effective at this eGFR, and it provides cardiovascular and
renal benefits that are independent of its glycemic effect.
C. Dapagliflozin should be avoided because it increases the risk of euglycemic diabetic
ketoacidosis, especially in patients on insulin.
D. Dapagliflozin is preferred because it enhances insulin sensitivity and reduces the
need for basal insulin without causing hypoglycemia.
Correct Answer: A. Dapagliflozin is contraindicated at this eGFR, and its glycemic
efficacy is diminished, so an alternative agent should be considered.
Rationale: SGLT2 inhibitors like dapagliflozin have reduced glycemic efficacy when eGFR
is below 45, and are not recommended for glycemic control at eGFR <45, though some
may be used for renal/cardiac benefits at lower eGFRs in certain guidelines. At eGFR 32,
it is generally not recommended for glucose lowering. The other options misstate the safet
y
profile or mechanism.
Why Wrong:
B - Incorrect: At eGFR 32, dapagliflozin is not recommended for glycemic control;
while it has renal benefits, it is not considered safe/effective for glucose lowering at
this level.
C - Incorrect: While euglycemic DKA is a risk, the primary issue at this eGFR is
reduced efficacy and lack of indication for glycemic control.
D - Incorrect: SGLT2 inhibitors do not enhance insulin sensitivity; they increase
urinary glucose excretion and may reduce insulin requirements but not via
sensitization.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48
Q2. A patient on warfarin for atrial fibrillation is diagnosed with an acute coronary
syndrome and requires dual antiplatelet therapy with aspirin and clopidogrel. Which
of the following best describes the evidence-based approach to minimize bleeding risk
while maintaining efficacy?
A. Triple therapy with warfarin, aspirin, and clopidogrel for at least 12 months is
recommended to prevent stent thrombosis.
B. Discontinue warfarin and use dual antiplatelet therapy alone, as the combination is
too risky.
C. Use a short duration of triple therapy (e.g., 1-4 weeks) followed by dual therapy
Page 3
, with an oral anticoagulant and a P2Y12 inhibitor, with gastroprotection.
D. Replace warfarin with a direct oral anticoagulant and continue dual antiplatelet
therapy indefinitely.
Correct Answer: C. Use a short duration of triple therapy (e.g., 1-4 weeks) followed
by dual therapy with an oral anticoagulant and a P2Y12 inhibitor, with
gastroprotection.
Rationale: Current guidelines recommend a short course of triple therapy (aspirin, P2Y12
inhibitor, and OAC) after ACS/stenting, often 1-4 weeks, then transition to dual therapy
with OAC and P2Y12 inhibitor to reduce bleeding. This is based on trials like RE-DUAL
PCI and PIONEER AF-PCI.
Why Wrong:
A - Incorrect: Prolonged triple therapy is associated with significantly higher bleeding
risk and is not recommended beyond the periprocedural period.
B - Incorrect: Discontinuing anticoagulation in AF increases stroke risk; dual therapy
with OAC and P2Y12 inhibitor is preferred.
D - Incorrect: Switching to DOAC is often done, but indefinite dual antiplatelet
therapy is not recommended; a limited duration is used.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with opioid use disorder is started on buprenorphine/naloxone. Which
of the following best describes the pharmacological rationale for including naloxone
in the combination product?
A. Naloxone is included to enhance the analgesic effect of buprenorphine by
preventing its metabolism.
B. Naloxone is added to deter intravenous misuse; when taken sublingually, naloxone
has poor bioavailability, but if crushed and injected, it precipitates withdrawal.
C. Naloxone is included to reduce the risk of respiratory depression by competing with
buprenorphine at mu receptors.
D. Naloxone is added to prolong the half-life of buprenorphine by inhibiting CYP3A4.
Correct Answer: B. Naloxone is added to deter intravenous misuse; when taken
sublingually, naloxone has poor bioavailability, but if crushed and injected, it
precipitates withdrawal.
Rationale: Sublingual naloxone has minimal systemic absorption, but if the tablet is
crushed and injected, naloxone becomes bioavailable and precipitates withdrawal,
deterring misuse. It does not enhance analgesia or alter buprenorphine's half-life.
Why Wrong:
A - Incorrect: Naloxone does not affect buprenorphine metabolism; it is an antagonist.
C - Incorrect: At sublingual doses, naloxone does not significantly block
buprenorphine's effects; the combination is intended to deter abuse, not reduce
Page 4
Verified Questions - 139 Questions with Answers
NR 565 Advanced Pharmacology Fundamentals Final Exam 2026-139 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for nursing students enrolled
in NR 565 Advanced Pharmacology Fundamentals at Chamberlain University. It features 200 verified
questions and answers that reflect the actual content and format of the 2026/2027 final exam. Each
question is accompanied by a detailed rationale to reinforce understanding of pharmacological
principles. This resource is designed to ensure a 100% guarantee of passing by providing the most
current and accurate study material available.
Key Features:
Pharmacokinetics and pharmacodynamics
Autonomic nervous system drugs
Cardiovascular pharmacology
Endocrine and metabolic disorders
Antimicrobial therapy
Special populations and safety
Updates for 2026:
- Updated to align with 2026/2027 Chamberlain curriculum changes
- Revised to include latest FDA drug approvals and safety alerts
- Enhanced rationales with evidence-based practice guidelines
- Added new questions on emerging pharmacogenomics and personalized medicine
- Reorganized content to mirror the exam blueprint weighting
Abstract:
This exam preparation document for NR 565 Advanced Pharmacology Fundamentals is a definitive resource for
nursing students seeking to excel in their final examination. Compiled from actual 2026/2027 exam questions, it
offers a comprehensive review of pharmacological principles essential for advanced nursing practice. The content
is systematically organized to cover major drug classes, mechanisms of action, therapeutic uses, adverse effects,
and nursing considerations. Each of the 200 questions is paired with a correct answer and a thorough rationale,
facilitating active learning and retention. The document also emphasizes clinical application, critical thinking, and
safe prescribing practices, aligning with the competencies expected of advanced practice nurses. By utilizing this
resource, students can confidently prepare for the exam and achieve a passing score with a 100% guarantee.
Keywords:
NR 565, Advanced Pharmacology, Final Exam, Chamberlain University, Verified Questions, Pharmacology
Fundamentals, 2026/2027, Nursing Exam Prep
Answer Format:
Each question is presented in a multiple-choice format, followed by the correct answer and a detailed rationale
explaining why it is correct and why the other options are incorrect. This format enhances understanding of
pharmacological concepts and supports critical thinking.
Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Reflects the latest 2026/2027 exam blueprint and guidelines
Includes evidence-based rationales for each answer
Page 1
, Covers all major content areas as per the course syllabus
Verified for accuracy by pharmacology experts
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 ADME, receptor interactions, dose-response, 15%
Pharmacodynamics drug metabolism
Autonomic Nervous System 31-60 cholinergic, anticholinergic, adrenergic, 15%
Drugs antiadrenergic
Cardiovascular Pharmacology 61-90 antihypertensives, antiarrhythmics, 15%
anticoagulants, lipid-lowering agents
Endocrine and Metabolic 91-120 insulin, oral hypoglycemics, thyroid 15%
Disorders hormones, corticosteroids
Antimicrobial Therapy 121-150 antibiotics, antivirals, antifungals, resistance 15%
mechanisms
Special Populations and Safety 151-200 pregnancy, pediatrics, geriatrics, drug 25%
interactions, adverse effects
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease (eGFR 32 mL/min/1.73
m²) is currently on metformin and insulin glargine. The provider considers adding
dapagliflozin. Which of the following best describes the pharmacological rationale
and safety consideration?
A. Dapagliflozin is contraindicated at this eGFR, and its glycemic efficacy is
diminished, so an alternative agent should be considered.
B. Dapagliflozin is safe and effective at this eGFR, and it provides cardiovascular and
renal benefits that are independent of its glycemic effect.
C. Dapagliflozin should be avoided because it increases the risk of euglycemic diabetic
ketoacidosis, especially in patients on insulin.
D. Dapagliflozin is preferred because it enhances insulin sensitivity and reduces the
need for basal insulin without causing hypoglycemia.
Correct Answer: A. Dapagliflozin is contraindicated at this eGFR, and its glycemic
efficacy is diminished, so an alternative agent should be considered.
Rationale: SGLT2 inhibitors like dapagliflozin have reduced glycemic efficacy when eGFR
is below 45, and are not recommended for glycemic control at eGFR <45, though some
may be used for renal/cardiac benefits at lower eGFRs in certain guidelines. At eGFR 32,
it is generally not recommended for glucose lowering. The other options misstate the safet
y
profile or mechanism.
Why Wrong:
B - Incorrect: At eGFR 32, dapagliflozin is not recommended for glycemic control;
while it has renal benefits, it is not considered safe/effective for glucose lowering at
this level.
C - Incorrect: While euglycemic DKA is a risk, the primary issue at this eGFR is
reduced efficacy and lack of indication for glycemic control.
D - Incorrect: SGLT2 inhibitors do not enhance insulin sensitivity; they increase
urinary glucose excretion and may reduce insulin requirements but not via
sensitization.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 48
Q2. A patient on warfarin for atrial fibrillation is diagnosed with an acute coronary
syndrome and requires dual antiplatelet therapy with aspirin and clopidogrel. Which
of the following best describes the evidence-based approach to minimize bleeding risk
while maintaining efficacy?
A. Triple therapy with warfarin, aspirin, and clopidogrel for at least 12 months is
recommended to prevent stent thrombosis.
B. Discontinue warfarin and use dual antiplatelet therapy alone, as the combination is
too risky.
C. Use a short duration of triple therapy (e.g., 1-4 weeks) followed by dual therapy
Page 3
, with an oral anticoagulant and a P2Y12 inhibitor, with gastroprotection.
D. Replace warfarin with a direct oral anticoagulant and continue dual antiplatelet
therapy indefinitely.
Correct Answer: C. Use a short duration of triple therapy (e.g., 1-4 weeks) followed
by dual therapy with an oral anticoagulant and a P2Y12 inhibitor, with
gastroprotection.
Rationale: Current guidelines recommend a short course of triple therapy (aspirin, P2Y12
inhibitor, and OAC) after ACS/stenting, often 1-4 weeks, then transition to dual therapy
with OAC and P2Y12 inhibitor to reduce bleeding. This is based on trials like RE-DUAL
PCI and PIONEER AF-PCI.
Why Wrong:
A - Incorrect: Prolonged triple therapy is associated with significantly higher bleeding
risk and is not recommended beyond the periprocedural period.
B - Incorrect: Discontinuing anticoagulation in AF increases stroke risk; dual therapy
with OAC and P2Y12 inhibitor is preferred.
D - Incorrect: Switching to DOAC is often done, but indefinite dual antiplatelet
therapy is not recommended; a limited duration is used.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 34
Q3. A patient with opioid use disorder is started on buprenorphine/naloxone. Which
of the following best describes the pharmacological rationale for including naloxone
in the combination product?
A. Naloxone is included to enhance the analgesic effect of buprenorphine by
preventing its metabolism.
B. Naloxone is added to deter intravenous misuse; when taken sublingually, naloxone
has poor bioavailability, but if crushed and injected, it precipitates withdrawal.
C. Naloxone is included to reduce the risk of respiratory depression by competing with
buprenorphine at mu receptors.
D. Naloxone is added to prolong the half-life of buprenorphine by inhibiting CYP3A4.
Correct Answer: B. Naloxone is added to deter intravenous misuse; when taken
sublingually, naloxone has poor bioavailability, but if crushed and injected, it
precipitates withdrawal.
Rationale: Sublingual naloxone has minimal systemic absorption, but if the tablet is
crushed and injected, naloxone becomes bioavailable and precipitates withdrawal,
deterring misuse. It does not enhance analgesia or alter buprenorphine's half-life.
Why Wrong:
A - Incorrect: Naloxone does not affect buprenorphine metabolism; it is an antagonist.
C - Incorrect: At sublingual doses, naloxone does not significantly block
buprenorphine's effects; the combination is intended to deter abuse, not reduce
Page 4
